Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
The purpose of this post-marketing surveillance study is to collect and assess information on
 safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE).

 ("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)
Inclusion Criteria:

 -  Patients with acute pulmonary thromboembolism or acute deep venous thrombosis

 -  Fondaparinux injection must be prescribed for the first time

 Exclusion Criteria:

 -  Not applicable